<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14376">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02919735</url>
  </required_header>
  <id_info>
    <org_study_id>ELAN</org_study_id>
    <nct_id>NCT02919735</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)</brief_title>
  <acronym>ELAN</acronym>
  <official_title>A Randomized, Double Blind, Single Center, Controlled Study to Compare the Efficacy, Safety and Tolerability of CG 428 Cutaneous Solution With Placebo on Alopecia in Cancer Female Patients Under Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Legacy Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Legacy Healthcare SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II clinical trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this trial is to compare the degree of efficacy, safety and tolerability of CG
      428 cutaneous solution versus placebo on prevention of chemotherapy induced alopecia (CIA)
      in female patients with metastatic cancer treated with selected regimens inducing alopecia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of hair loss at different time points based on Olsen's Visual Analog Scale</measure>
    <time_frame>Every 3 weeks for 24 weeks.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of grade 2 alopecia according to CTCAE v. 4.03.</measure>
    <time_frame>Every 3 weeks for 24 weeks.</time_frame>
    <description>CTCAE v. 4.03 : Common Toxicity Criteria for Adverse Event (skin toxicity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach grade 2 alopecia during chemotherapy according to CTCAE v. 4.03</measure>
    <time_frame>Every 3 weeks for 24 weeks.</time_frame>
    <description>CTCAE v. 4.03 : Common Toxicity Criteria for Adverse Event (skin toxicity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recover to grade 1 and grade 0 according to CTCAE v. 4.03 after the last dose of the selected chemotherapy</measure>
    <time_frame>Every 3 weeks for 24 weeks.</time_frame>
    <description>CTCAE v. 4.03 : Common Toxicity Criteria for Adverse Event (skin toxicity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of hair loss according to Olsen's visual analog scale (OVAS) at different time points after the end of the chemotherapy</measure>
    <time_frame>Every 3 weeks for 24 weeks.</time_frame>
    <description>Olsen's visual analog scale : visual aid for estimating percentage scalp hair loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events based on the CTCAE 4.03.</measure>
    <time_frame>Every 3 weeks for 24 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's subjective assessment through questionnaire</measure>
    <time_frame>Every 3 weeks for 24 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Alopecia</condition>
  <arm_group>
    <arm_group_label>CG 428 cutaneous solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Herbal Medicinal Product, topical use by spray on the scalp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cutaneous solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, topical use by spray on the scalp</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG 428 cutaneous solution</intervention_name>
    <description>The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours</description>
    <arm_group_label>CG 428 cutaneous solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo cutaneous solution</intervention_name>
    <description>The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours</description>
    <arm_group_label>Placebo cutaneous solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult female, age ≥ 18 years.

          -  Advanced stage cancer, requiring one of the following pre-specified chemotherapy
             regimen according to local guidelines: weekly paclitaxel, weekly docetaxel, eribulin
             or association of weekly paclitaxel/docetaxel with carboplatine.

          -  Healthy hair (no current alopecia or scalp disease treatment).

          -  Life expectancy ≥ 6 months.

          -  Able to use the study treatment in compliance with the protocol.

          -  Physical and psychological ability to participate.

          -  Negative serum pregnancy test within 14 days prior to randomization in premenopausal
             women with childbearing potential.

          -  Patients must agree to not shave their head (minimum ≥ 1 cm).

          -  Signed and dated informed consent.

        Exclusion Criteria:

          -  Other ongoing anti-neoplastic therapy or other investigational drug with potential
             effect on hair growth.

          -  Prior radiotherapy to the scalp with residual alopecia.

          -  Known allergy or hypersensitivity to some components of CG 428 cutaneous solution
             (including allium cepa (onion), citrus, caffeine, theobromine).

          -  Pre-existing alopecia or significant scalp disease, which may alter study treatment
             administration or absorption.

          -  Concomitant use of cold cap or any other anti-hair loss treatment.

          -  Hair transplants.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khalil KZ ZAMAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department Oncology - CHUV, 1011 Lausanne - CH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khalil KZ ZAMAN, PhD</last_name>
    <phone>+41 79 556 78 01</phone>
    <email>khalil.zaman@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole NJ JAMES FARESSE, PhD</last_name>
    <phone>+41 21 314 33 69</phone>
    <email>Nicole.James-Faresse@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHUV Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalil KZ ZAMAN, PhD</last_name>
      <phone>+41795567801</phone>
      <email>khalil.zaman@chuv.ch</email>
    </contact>
    <contact_backup>
      <last_name>Nicole NJ JAMES FARESSE, PhD</last_name>
      <phone>+41213143369</phone>
      <email>Nicole.James-Faresse@chuv.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 10, 2016</lastchanged_date>
  <firstreceived_date>September 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alopecia</keyword>
  <keyword>Hair</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
